Bayer HealthCare and Onyx Pharmaceuticals Inc. announced that a Phase III trial evaluating Nexavar tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer did not meet its primary endpoint of improving overall survival. An improvement in the secondary endpoint of progression-free survival was also observed.
The trial compared Nexavar plus best supportive care to placebo plus best supportive care. The safety and tolerability data were generally as anticipated. The MISSION study was conducted at over 150 sites in North America, South America, Europe, Africa and the Asia-Pacific region, including Japan.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.